Sequencing Immunotherapy in Advanced-Stage Lung Cancer

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.<br /> &nbsp;

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.

There had been a lot of debate about the timing of when patients should receive a PD-1 inhibitor, Garon explains.

Results of the KEYNOTE-024 study ended that debate when they showed patients with high levels of staining for PD-L1 were more likely to have an improvement in progression-free survival (PFS) if they received pembrolizumab (Keytruda) over chemotherapy. Additionally, there was a survival advantage seen in patients who received the PD-1 inhibitor as their initial therapy.

There is now a debate once again with the approval of carboplatin, pemetrexed, and pembrolizumab, based on results of the KEYNOTE-021 study.